催产素对肥胖成人游离T3/游离T4比值的影响及其与生活质量的关系
CONTEXT: Oxytocin (OXT) is an anorexigenic, anxiolytic, and antidepressant neurohormone under investigation for obesity treatment. Mechanisms underlying OXT psychological effects are not fully understood, and human data on OXT modulation of the thyroid axis are lacking.…
要点
- 鼻内催产素6周可升高肥胖成人fT3/fT4比值,安慰剂组无变化。
- 催产素改变了fT3/fT4变化与心理健康生活质量变化的关系。
核心结论
- 与安慰剂相比,长期催产素治疗增加fT3/fT4并影响fT3/fT4与MHQoL变化的关系,fT3/fT4与MHQoL变化评分呈趋势性正相关。
- 催产素对fT3/fT4的作用可能解释其带来的心理健康益处。
研究设计与样本
- 八周随机临床试验的二次分析,在三级学术中心进行。
- 主要结局指标为治疗前和治疗后第6周空腹甲状腺激素及第8周MHQoL。
临床怎么用
- 在肥胖成人中,鼻内催产素可能通过调节fT3/fT4比值改善心理健康相关生活质量,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Oxytocin (OXT) is an anorexigenic, anxiolytic, and antidepressant neurohormone under investigation for obesity treatment. Mechanisms underlying OXT psychological effects are not fully understood, and human data on OXT modulation of the thyroid axis are lacking. Our 8-week trial of intranasal OXT in adults with obesity showed improved mental health-related quality of life (MHQoL) measured by the Short-Form 36 Health Survey vs placebo. Increased T4 and decreased T3 have been linked to depression. The free (bioactive) T3 (fT3)/free T4 (fT4) ratio, a marker of thyroid function in euthyroid patients, is associated with improved mental health. OBJECTIVE: To determine whether 6 weeks of intranasal OXT vs placebo modulates (1) the thyroid axis and (2) the relationship between fT3/fT4 and MHQoL changes. DESIGN: Eight-week randomized clinical trial, secondary analysis. SETTING: Tertiary academic center. PARTICIPANTS: Sixty-one adults with obesity. INTERVENTIONS: Eight weeks of intranasal OXT (24 IU) 4× daily or placebo. MAIN OUTCOME MEASURES: Pre- and posttreatment fasting thyroid hormones (week 6) and MHQoL (week 8). RESULTS: Six weeks of intranasal OXT vs placebo impacted fT3/fT4 (treatment × time P = .045), with an increase in the OXT group (P = .048) and no change in the placebo group (P = .406). TSH, fT4, and fT3 did not change (P ≥ .154). OXT vs placebo impacted the relationship between fT3/fT4 (6 weeks) and MHQoL (8 weeks) changes (treatment × Δ[fT3/fT4] P = .023); increased fT3/fT4 was positively associated with MHQoL improvement (trend-level P = .088). CONCLUSION: Prolonged OXT vs placebo increased fT3/fT4 and impacted the relationship between fT3/fT4 and MHQoL changes, with a trend-level positive correlation between fT3/fT4 and MHQoL change scores. OXT action on fT3/fT4 may underpin OXT-induced mental health benefits. CLINICAL TRIAL REGISTRATION: NCT03043053.
引用
- Galbiati F, Wronski ML, Bitar T, et al. Oxytocin-induced changes in free T3/free T4 ratio and relationship with quality of life in adults with obesity. J Clin Endocrinol Metab. 2026. PMID: 42714565. doi:10.1210/clinem/dgag291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。